Tested new chemo combination versus standard care for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 60
- Your cancer is newly diagnosed and is the non-keratinizing type
- Your overall health is good enough for treatment (ECOG 0 to 1)
- Your cancer stage is AJCC III to IVA (with an exception for T3-4 N0)
- Your blood counts and liver/kidney tests are strong enough for chemotherapy
- You can use the study treatment plan, understand it’s experimental, and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy drugs—nedaplatin versus cisplatin—in people newly diagnosed with a specific type of nasopharyngeal cancer. The goal is to see which drug works better and/or has a safer side-effect profile when given as part of standard treatment.
This trial studies whether adding targeted radiotherapy (SBRT) to PD-1 immunotherapy plus capecitabine can improve outcomes for people with newly diagnosed metastatic nasopharyngeal cancer. You may be eligible if your cancer has responded at least to “stable disease” after an initial chemo-immunotherapy course.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.